Is ArriVent BioPharma, Stock a Good Investment?
ArriVent BioPharma, Investment Advice | AVBP |
- Examine ArriVent BioPharma,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ArriVent BioPharma,'s leadership team and their track record. Good management can help ArriVent BioPharma, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ArriVent BioPharma,'s business and its evolving consumer preferences.
- Compare ArriVent BioPharma,'s performance and market position to its competitors. Analyze how ArriVent BioPharma, is positioned in terms of product offerings, innovation, and market share.
- Check if ArriVent BioPharma, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ArriVent BioPharma,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ArriVent BioPharma, Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ArriVent BioPharma, Common is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ArriVent BioPharma, Stock
Researching ArriVent BioPharma,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 85.0% of the company shares are held by institutions such as insurance companies. The book value of ArriVent BioPharma, was presently reported as 7.64. The company recorded a loss per share of 2.56. ArriVent BioPharma, had not issued any dividends in recent years.
To determine if ArriVent BioPharma, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ArriVent BioPharma,'s research are outlined below:
| ArriVent BioPharma, generated a negative expected return over the last 90 days | |
| ArriVent BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (80.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ArriVent BioPharma, generates negative cash flow from operations | |
| ArriVent BioPharma, has a poor financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: ArriVent BioPharma Expected to Announce Earnings on Thursday |
ArriVent BioPharma, Quarterly Liabilities And Stockholders Equity |
|
Earnings surprises can significantly impact ArriVent BioPharma,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ArriVent BioPharma,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-15 | 2024-06-30 | -0.5884 | -0.65 | -0.0616 | 10 | ||
2024-12-31 | 2024-12-31 | -0.7814 | -0.61 | 0.1714 | 21 | ||
2024-03-28 | 2023-12-31 | -1.1 | -0.7 | 0.4 | 36 | ||
2024-11-14 | 2024-09-30 | -1.0671 | -0.61 | 0.4571 | 42 | ||
2024-05-08 | 2024-03-31 | -1.2963 | -0.7 | 0.5963 | 46 |
ArriVent BioPharma, Target Price Consensus
ArriVent target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. ArriVent BioPharma,'s target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most ArriVent analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand ArriVent stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of ArriVent BioPharma,, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationArriVent BioPharma, Target Price Projection
ArriVent BioPharma,'s current and average target prices are 18.57 and 38.00, respectively. The current price of ArriVent BioPharma, is the price at which ArriVent BioPharma, Common is currently trading. On the other hand, ArriVent BioPharma,'s target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
ArriVent BioPharma, Market Quote on 27th of March 2025
Target Price
Analyst Consensus On ArriVent BioPharma, Target Price
ArriVent BioPharma, Analyst Ratings
ArriVent BioPharma,'s analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about ArriVent BioPharma, stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of ArriVent BioPharma,'s financials, market performance, and future outlook by experienced professionals. ArriVent BioPharma,'s historical ratings below, therefore, can serve as a valuable tool for investors.ArriVent BioPharma,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 645.97 M.Market Cap |
|
ArriVent BioPharma,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.57) | (0.59) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.31) | (0.33) |
Determining ArriVent BioPharma,'s profitability involves analyzing its financial statements and using various financial metrics to determine if ArriVent BioPharma, is a good buy. For example, gross profit margin measures ArriVent BioPharma,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ArriVent BioPharma,'s profitability and make more informed investment decisions.
Basic technical analysis of ArriVent Stock
As of the 27th of March, ArriVent BioPharma, shows the Standard Deviation of 2.93, risk adjusted performance of (0.13), and Mean Deviation of 2.25. ArriVent BioPharma, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.ArriVent BioPharma,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ArriVent BioPharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on ArriVent BioPharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ArriVent BioPharma, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orbimed Advisors Llc few days ago Discretionary transaction by Orbimed Advisors Llc of 821827 shares of ArriVent BioPharma, subject to Rule 16b-3 | ||
Hillhouse Investment Management, Ltd. over six months ago Acquisition by Hillhouse Investment Management, Ltd. of 555555 shares of ArriVent BioPharma, at 18.0 subject to Rule 16b-3 | ||
Hillhouse Investment Management Ltd over a year ago Conversion by Hillhouse Investment Management Ltd of 3616041 shares of ArriVent BioPharma, | ||
Gordon Carl L over a year ago Conversion by Gordon Carl L of 821827 shares of ArriVent BioPharma, | ||
Gordon Carl L over a year ago Conversion by Gordon Carl L of 469615 shares of ArriVent BioPharma | ||
Jallal Bahija over a year ago Acquisition by Jallal Bahija of 17884 shares of ArriVent BioPharma, subject to Rule 16b-3 | ||
Gordon Carl L over a year ago ArriVent BioPharma exotic insider transaction detected |
ArriVent BioPharma,'s Outstanding Corporate Bonds
ArriVent BioPharma, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ArriVent BioPharma, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ArriVent bonds can be classified according to their maturity, which is the date when ArriVent BioPharma, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ARROW ELECTRS INC Corp BondUS042735BE98 | View | |
| ARROW ELECTRS INC Corp BondUS042735BF63 | View | |
| ARW 295 15 FEB 32 Corp BondUS04273WAC55 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| ARROW ELECTRS INC Corp BondUS042735AK67 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand ArriVent BioPharma,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ArriVent BioPharma,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.36) | |||
| Mean Deviation | 2.25 | |||
| Coefficient Of Variation | (616.08) | |||
| Standard Deviation | 2.93 | |||
| Variance | 8.58 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.37) | |||
| Maximum Drawdown | 11.91 | |||
| Value At Risk | (6.39) | |||
| Potential Upside | 3.57 | |||
| Skewness | (0.46) | |||
| Kurtosis | (0.21) |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.36) | |||
| Mean Deviation | 2.25 | |||
| Coefficient Of Variation | (616.08) | |||
| Standard Deviation | 2.93 | |||
| Variance | 8.58 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.37) | |||
| Maximum Drawdown | 11.91 | |||
| Value At Risk | (6.39) | |||
| Potential Upside | 3.57 | |||
| Skewness | (0.46) | |||
| Kurtosis | (0.21) |
Consider ArriVent BioPharma,'s intraday indicators
ArriVent BioPharma, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ArriVent BioPharma, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ArriVent BioPharma, Corporate Filings
8K | 13th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 3rd of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 14th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
ASR | 3rd of February 2025 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
ArriVent Stock media impact
Far too much social signal, news, headlines, and media speculation about ArriVent BioPharma, that are available to investors today. That information is available publicly through ArriVent media outlets and privately through word of mouth or via ArriVent internal channels. However, regardless of the origin, that massive amount of ArriVent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ArriVent BioPharma, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ArriVent BioPharma, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ArriVent BioPharma,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ArriVent BioPharma, alpha.
ArriVent BioPharma, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ArriVent BioPharma, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ArriVent BioPharma, Corporate Executives
Elected by the shareholders, the ArriVent BioPharma,'s board of directors comprises two types of representatives: ArriVent BioPharma, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ArriVent. The board's role is to monitor ArriVent BioPharma,'s management team and ensure that shareholders' interests are well served. ArriVent BioPharma,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ArriVent BioPharma,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Winston MBA | CFO Treasurer | Profile | |
| Robin MA | CoFounder COO | Profile |
Already Invested in ArriVent BioPharma, Common?
The danger of trading ArriVent BioPharma, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ArriVent BioPharma, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ArriVent BioPharma,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ArriVent BioPharma, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.